Stereotyped patterns of somatic hypermutation in subsets of patients with chronic lymphocytic leukemia: Implications for the role of antigen selection in leukemogenesis

Blood

Volumn 111, Issue 3, 2008, Pages 1524-1533

  Murray, Fiona ^a   Darzentas, Nikos ^b   Hadzidimitriou, Anastasia ^b,c   Tobin, Gerard ^a   Boudjogra, Myriam ^d   Scielzo, Cristina ^e   Laoutaris, Nikolaos ^f   Karlsson, Karin ^g   Baran Marzsak, Fanny ^h   Tsaftaris, Athanasios ^b   Moreno, Carol ⁱ   Anagnostopoulos, Achilles ^c   Caligaris Cappio, Federico ^e   Vaur, Dominique ^j   Ouzounis, Christos ^b   Belessi, Chrysoula ^f   Ghia, Paolo ^e,k   Davi, Fred ^d   Rosenquist, Richard ^a   Stamatopoulos, Kostas ^c  

^a UPPSALA UNIVERSITY   (Sweden)

^b Centre for Research and Technology   (Greece)

^c G PAPANICOLAOU HOSPITAL   (Greece)

^d SORBONNE UNIVERSITÉ   (France)

^e SAN RAFFAELE HOSPITAL   (Italy)

^f Nikea General Hospital Athens   (Greece)

^g LUND UNIVERSITY HOSPITAL   (Sweden)

^h UNIVERSITÉ PARIS 13   (France)

ⁱ UNIVERSITY OF BARCELONA   (Spain)

^j CENTRE FRANÇOIS BACLESSE   (France)

^k VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN;

AMINO ACID SEQUENCE; ANTIGEN RECOGNITION; ARTICLE; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; GENE EXPRESSION; GENE REARRANGEMENT; GENE SEQUENCE; HUMAN; IMMUNOGLOBULIN HEAVY CHAIN GENE; MAJOR CLINICAL STUDY; PATHOGENESIS; PRIORITY JOURNAL; SOMATIC HYPERMUTATION; STEREOTYPY;

EID: 38949203770     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2007-07-099564     Document Type: Article

References (86)

1. Maizels N. Immunoglobulin gene diversification. Annu Rev Genet. 2005;39:23-46.
2. Davies DR, Padlan EA, Sheriff S. Antibody-antigen complexes. Annu Rev Biochem. 1990;59:439-473.
3. Davies DR, Cohen GH. Interactions of protein antigens with antibodies. Proc Natl Acad Sci U S A. 1996;93:7-12.
4. Xu JL, Davis MM. Diversity in the CDR3 region of V(H) is sufficient for most antibody specificities. Immunity. 2000;13:37-45.
5. Silverman GJ, Goodyear CS. A model B-cell superantigen and the immunobiology of B lymphocytes. Clin Immunol. 2002;102:117-134.
6. Di Noia JM, Neuberger MS. Molecular mechanisms of antibody somatic hypermutation. Annu Rev Biochem. 2007;76:1-22.
7. Manser T. Textbook germinal centers? J Immunol. 2004;172:3369-3375.
8. De Vinuesa CG, Cook M, Ball C, et al. Germinal centers without T cells. J Exp Med. 2000;191:485-494.
9. Weller SA, Faili C, Garcia MC, et al. CD40-CD40L independent Ig gene hypermutation suggests a second B cell diversification pathway in humans. Proc Natl Acad Sci U S A. 2001;98:1166-1170.
10. William J, Euler C, Christensen S, Shlomchik MJ. Evolution of autoantibody responses via somatic hypermutation outside of germinal centers. Science. 2002;297:2066-2070.
11. Weller S, Braun MC, Tan BK, et al. Human blood IgM "memory" B cells are circulating splenic marginal zone B cells harboring a prediversified immunoglobulin repertoire. Blood. 2004;104:3647-3654.
12. Kruetzmann S, Rosado MM, Weber H, et al. Human immunoglobulin M memory B cells controlling Streptococcus pneumoniae infections are generated in the spleen. J Exp Med. 2003;197:939-945.
13. Weller S, Reynaud CA, Weill JC. Vaccination against encapsulated bacteria in humans: paradoxes. Trends Immunol. 2005;26:85-89.
14. Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med. 2005;352:804-815.
15. Dighiero G. CLL biology and prognosis. Hematology Am Soc Hematol Educ Program. 2005;278-284.
16. Schroeder HW Jr, Dighiero G. The pathogenesis of chronic lymphocytic leukemia: analysis of the antibody repertoire. Immunol Today. 1994;15:288-294.
17. Ghia P, Stamatopoulos K, Belessi C, et al. European Research Initiative on CLL: ERIC recommendations on IGHV gene mutational status analysis in chronic lymphocytic leukemia. Leukemia. 2007;21:1-3.
18. Damle RN, Wasil T, Fais F, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood. 1999;94:1840-1847.
19. Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood. 1999;94:1848-1854.
20. Damle RN, Ghiotto F, Valetto A, et al. B-cell chronic lymphocytic leukemia cells express a surface membrane phenotype of activated, antigen-experienced B lymphocytes. Blood. 2002;99:4087-4093.
21. Stevenson FK, Caligaris-Cappio F. Chronic lymphocytic leukemia: revelations from the B-cell receptor. Blood. 2004;103:4389-4395.
22. Rosenwald A, Alizadeh AA, Widhopf G, et al. Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med. 2001;194:1639-1647.
23. Klein U, Tu Y, Stolovitzky GA, et al. Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells. J Exp Med. 2001;194:1625-1638.
24. Fais F, Ghiotto F, Hashimoto S, et al. Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors. J Clin Invest. 1998;102:1515-1525.
25. Tobin G, Thunberg U, Johnson A, et al. Somatically mutated Ig V(H)3-21 genes characterize a new subset of chronic lymphocytic leukemia. Blood. 2002;99:2262-2264.
26. Chiorazzi N, Ferrarini M. B cell chronic lymphocytic leukemia: lessons learned from studies of the B cell antigen receptor. Annu Rev Immunol. 2003;21:841-894.
27. Ghia P, Stamatopoulos K, Belessi C, et al. Geographic patterns and pathogenetic implications of IGHV gene usage in chronic lymphocytic leukemia: the lesson of the IGHV3-21 gene. Blood. 2005;105:1678-1685.
28. Widhopf GF 2nd, Kipps TJ. Normal B cells express 51p1-encoded Ig heavy chains that are distinct from those expressed by chronic lymphocytic leukemia B cells. J Immunol. 2001;166:95-102.
29. Tobin G, Thunberg U, Johnson A, et al. Chronic lymphocytic leukemias utilizing the VH3-21 gene display highly restricted Vlambda2-14 gene use and homologous CDR3s: implicating recognition of a common antigen epitope. Blood. 2003;101:4952-4957.
30. Ghiotto F, Fais F, Valetto A, et al. Remarkably similar antigen receptors among a subset of patients with chronic lymphocytic leukemia. J Clin Invest. 2004;113:1008-1016.
31. Widhopf GF 2nd, Rassenti LZ, Toy TL, Gribben JG, Wierda WG, Kipps TJ. Chronic lymphocytic leukemia B cells of more than 1% of patients express virtually identical immunoglobulins. Blood. 2004;104:2499-2504.
32. Messmer BT, Albesiano E, Efremov DG, et al. Multiple distinct sets of stereotyped antigen receptors indicate a role for antigen in promoting chronic lymphocytic leukemia. J Exp Med. 2004;200:519-525.
33. Tobin G, Thunberg U, Karlsson K, et al. Subsets with restricted immunoglobulin gene rearrangement features indicate a role for antigen selection in the development of chronic lymphocytic leukemia. Blood. 2004;104:2879-2885.
34. Stamatopoulos K, Belessi C, Moreno C, et al. Over 20% of patients with chronic lymphocytic leukemia carry stereotyped receptors: pathogenetic implications and clinical correlations. Blood. 2007;109:259-270.
35. Thorselius M, Krober A, Murray F, et al. Strikingly homologous immunoglobulin gene rearrangements and poor outcome in VH3-21-utilizing chronic lymphocytic leukemia independent of geographical origin and mutational status. Blood. 2006;107:2889-2894.
36. Potter KN, Mockridge CI, Neville L, et al. Structural and functional features of the B-cell receptor in IgG-positive chronic lymphocytic leukemia. Clin Cancer Res. 2006;12:1672-1679.
37. Belessi CJ, Davi FB, Stamatopoulos KE, et al. IGHV gene insertions and deletions in chronic lymphocytic leukemia: "CLL-biased" deletions in a subset of cases with stereotyped receptors. Eur J Immunol. 2006;36:1963-1974.
38. Cheson BD, Bennett JM, Grever M, et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood. 1996;87:4990-4997.
39. van Dongen JJ, Langerak AW, Bruggemann M, et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia. 2003;17:2257-2317.
40. Lefranc MP, Giudicelli V, Kaas Q, et al. IMGT, the international ImMunoGeneTics information system. Nucleic Acids Res. 2005;33:D593-D597.
41. Giudicelli V, Chaume D, Lefranc MP. IMGT/VQUEST, an integrated software program for immunoglobulin and T cell receptor V-J and V-D-J rearrangement analysis. Nucleic Acids Res. 2004;32(Web Server issue):W435-W440.
42. Nelson DL, Cox MM, eds. Lehninger Principles of Biochemistry. New York, NY: Freeman; 2005.
43. Pommie C, Levadoux S, Sabatier R, Lefranc G, Lefranc MP. IMGT standardized criteria for statistical analysis of immunoglobulin V-REGION amino acid properties. J Mol Recognit. 2004;17:17-32.
44. Rogozin IB, Pavlov YI. Theoretical analysis of mutation hotspots and their DNA sequence context specificity. Mutat Res. 2003;544:65-85.
45. Rogozin IB, Diaz M. Cutting edge: DGYW/WRCH is a better predictor of mutability at G:C bases in Ig hypermutation than the widely accepted RGYW/WRCY motif and probably reflects a twostep activation-induced cytidine deaminase-triggered process. J Immunol. 2004;172:3382-3384.
46. Rogozin I, Kolchanov N. Somatic hypermutagenesis in immunoglobulin genes: II. Influence of neighbouring base sequences on mutagenesis. Biochim Biophys Acta. 1992;1171:11-18.
47. Goyenechea B, Milstein C. Modifying the sequence of an immunoglobulin V-gene alters the resulting pattern of hypermutation. Proc Natl Acad Sci U S A. 1996; 93:13979-13984.
48. Potter KN, Hobby P, Klijn S, Stevenson FK, Sutton BJ. Evidence for involvement of a hydrophobic patch in framework region 1 of human V4-34-encoded Igs in recognition of the red blood cell I antigen. J Immunol. 2002;169:3777-3782.
49. Longo NS, Lipsky PE. Why do B cells mutate their immunoglobulin receptors? Trends Immunol. 2006;27:374-380.
50. Herve M, Xu K, Ng YS, et al. Unmutated and mutated chronic lymphocytic leukemias derive from self-reactive B cell precursors despite expressing different antibody reactivity. J Clin Invest. 2005;115:1636-1643.
51. Mouthon L, Nobrega A, Nicolas N, et al. Invariance and restriction toward a limited set of selfantigens characterize neonatal IgM antibody repertoires and prevail in autoreactive repertoires of healthy adults. Proc Natl Acad Sci U S A. 1995;92:3839-3843.
52. Jang YJ, Stollar BD. Anti-DNA antibodies: aspects of structure and pathogenicity. Cell Mol Life Sci. 2003;60:309-320.
53. Claflin JL, Berry J. Genetics of the phosphocholine-specific antibody response to Streptococcus pneumoniae: germ-line but not mutated T15 antibodies are dominantly selected. J Immunol. 1988;141:4012-4019.
54. Hangartner L, Zinkernagel RM, Hengartner H. Antiviral antibody responses: the two extremes of a wide spectrum. Nat Rev Immunol. 2006;6:231-243.
55. Barbas SM, Ditzel HJ, Salonen EM, Yang WP, Silverman GJ, Burton DR. Human autoantibody recognition of DNA. Proc Natl Acad Sci U S A. 1995;92:2529-2533.
56. Cocca BA, Seal SN, D'Agnillo P, et al. Structural basis for autoantibody recognition of phosphatidylserine-beta 2 glycoprotein I and apoptotic cells. Proc Natl Acad Sci U S A. 2001;98:13826-13831.
57. Rahman A, Giles I, Haley J, Isenberg D. Systematic analysis of sequences of anti-DNA antibodies-relevance to theories of origin and pathogenicity. Lupus. 2002;11:807-823.
58. Zheng NY, Wilson K, Jared M, Wilson PC. Intricate targeting of immunoglobulin somatic hypermutation maximizes the efficiency of affinity maturation. J Exp Med. 2005;201:1467-1478.
59. Clark LA, Ganesan S, Papp S, van Vlijmen HW. Trends in antibody sequence changes during the somatic hypermutation process. J Immunol. 2006;177:333-340.
60. Silberstein LE, George A, Durdik JM, Kipps TJ. The V4-34 encoded anti-i autoantibodies recognize a large subset of human and mouse B-cells. Blood Cells Mol Dis. 1996;22:126-138.
61. Beppu M, Ando K, Saeki M, Yokoyama N, Kikugawa K. Binding of oxidized Jurkat cells to THP-1 macrophages and antiband 3 IgG through sialylated poly-N-acetyllactosaminyl sugar chains. Arch Biochem Biophys. 2000;384:368-374.
62. Renno T, Attinger A, Rimoldi D, Hahne M, Tschopp J, MacDonald HR. Expression of B220 on activated T cell blasts precedes apoptosis. Eur J Immunol. 1998;28:540-547.
63. Pugh-Bernard A, Hocknell K, Cappione A, Anolik J, Sanz I. VH4-34 anti-I/i autoantibodies recognize apoptotic cells. Arthritis Rheum. 2000;46:S126.
64. Shaw PX, Horkko S, Chang MK, et al. Natural antibodies with the T15 idiotype may act in atherosclerosis, apoptotic clearance, and protective immunity. J Clin Invest. 2000;105:1731-1740.
65. Bhat NM, Bieber MM, Chapman CJ, Stevenson FK, Teng NN. Human antilipid A monoclonal antibodies bind to human B cells and the i antigen on cord red blood cells. J Immunol. 1993;151:5011-5021.
66. Spellerberg MB, Chapman CJ, Mockridge CI, Isenberg DA, Stevenson FK. Dual recognition of lipid A and DNA by human antibodies encoded by the VH4-21 gene: a possible link between infection and lupus. Hum Antibodies Hybridomas. 1995;6:52-56.
67. Thomas MD, Clough K, Melamed MD, et al. A human monoclonal antibody encoded by the V4-34 gene segment recognises melanoma-associated ganglioside via CDR3 and FWR1. Hum Antibodies. 1999;9:95-106.
68. Pugh-Bernard AE, Silverman GJ, Cappione AJ, et al. Regulation of inherently autoreactive VH4-34 B cells in the maintenance of human B cell tolerance. J Clin Invest. 2001;108:1061-1070.
69. Li Y, Li H, Ni D, Weigert M. Anti-DNA B cells in MRL/lpr mice show altered differentiation and editing pattern. J Exp Med. 2002;196:1543-1552.
70. Li H, Jiang Y, Prak EL, Radic M, Weigert M. Editors and editing of anti-DNA receptors. Immunity. 2001;15:947-957.
71. Bhat NM, Bieber MM, Spellerberg MB, Stevenson FK, Teng NN. Recognition of auto- and exoantigens by V4-34 gene encoded antibodies. Scand J Immunol. 2000;51:134-140.
72. Catera R, Hatzi K, Chu C, et al. Polyreactive monoclonal antibodies synthesized by some BCLL cells recognize specific antigens on viable and apoptotic T cells [abstract]. Blood. 2006;108:2813.
73. Li Y-C, Spellerberg MB, Stevenson FK, Capra JD, Potter KN. The I binding specificity of human VH4-34 (VH4.21) encoded antibodies is determined by both VH framework region 1 and complementarity determining region 3. J Mol Biol. 1996;256:577-589.
74. Bhat NM, Bieber MM, Hsu FJ, et al. Rapid cytotoxicity of human B lymphocytes induced by VH4-34 (VH4.21) gene encoded monoclonal antibodies, II. Clin Exp Immunol. 1997;108:151-159.
75. Bhat NM, Lee LM, van Vollenhoven RF, Teng NN, Bieber MM. VH4-34-encoded antibody in systemic lupus erythematosus: effect of isotype. J Rheumatol. 2002;29:2114-2121.
76. Jang YJ, Stollar BD. Anti-DNA antibodies: aspects of structure and pathogenicity. Cell Mol Life Sci. 2003;60:309-320.
77. Li Z, Schettino EW, Padlan EA, Ikematsu H, Casali P. Structure-function analysis of a lupus anti-DNA autoantibody: central role of the heavy chain complementarity-determining region 3 Arg in binding of double- and single-stranded DNA. Eur J Immunol. 2000;30:2015-2026.
78. Krishnan MR, Jou NT, Marion TN. Correlation between the amino acid position of arginine in VH-CDR3 and specificity for native DNA among autoimmune antibodies. J Immunol. 1996;157:2430-2439.
79. Behrendt M, Partridge LJ, Griffiths B, Goodfield M, Snaith M, Lindsey NJ. The role of somatic mutation in determining the affinity of anti-DNA antibodies. Clin Exp Immunol. 2003;131:182-189.
80. Chapman CJ, Spellerberg MB, Hamblin TJ, Stevenson FK. Pattern of usage of the VH4-21 gene by B lymphocytes in a patient with EBV infection indicates ongoing mutation and class switching. Mol Immunol. 1995;32:347-353.
81. McClain MT, Heinlen LD, Dennis GJ, Roebuck J, Harley JB, James JA. Early events in lupus humoral autoimmunity suggest initiation through molecular mimicry. Nat Med. 2005;11:85-89.
82. Sundar K, Jacques S, Gottlieb P, et al. Expression of the Epstein-Barr virus nuclear antigen-1 (EBNA-1) in the mouse can elicit the production of anti-dsDNA and anti-Sm antibodies. J Autoimmun. 2004;23:127-140.
83. Isenberg D, Spellerberg M, Williams W, Griffiths M, Stevenson F. Identification of the 9G4 idiotope in systemic lupus erythematosus. Br J Rheumatol. 1993;32:876-882.
84. Isenberg DA, McClure C, Farewell V, et al. Correlation of 9G4 idiotope with disease activity in patients with systemic lupus erythematosus. Ann Rheum Dis. 1998;57:566-570.
85. Schneider T, Stephens R. Sequence logos: a new way to display consensus sequences. Nucleic Acids Res. 1990;18:6097-6100.
86. Beitz E. Subfamily logos: visualization of sequence deviations at alignment positions with high information content. BMC Bioinformatics. 2006;7:313.